Loading…
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-29M | $-30M | $-28M | -145.5% | - | 38.6% |
| 2024 | $0M | $-17M | $-22M | $-15M | -151.5% | - | -26.0% |
| 2023 | $0M | $-29M | $-29M | $-12M | 1860.6% | - | 213.0% |
| 2022 | $0M | $-9M | $-9M | $-8M | -76.2% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 9.72 | 13.17 | 17.15 | 27.29 |
| Research And Development | - | 7.93 | 9.40 | 13.34 | 20.53 |
| Selling General And Administration | - | 2.01 | 4.14 | 3.87 | 7.58 |
| Total Expenses | - | 9.72 | 13.17 | 17.15 | 27.29 |
| Operating Income | - | -9.72 | -13.17 | -17.15 | -27.29 |
| Total Operating Income As Reported | - | -9.93 | -29.76 | -17.65 | -31.80 |
| EBITDA | - | -8.99 | -29.12 | -17.43 | -29.36 |
| Normalized EBITDA | - | -9.29 | -12.90 | -16.67 | -27.08 |
| EBIT | - | -9.37 | -29.30 | -17.54 | -29.43 |
| Interest Income | - | 0.06 | 0.09 | 0.36 | 0.14 |
| Interest Expense | - | 0 | 0.02 | 4.14 | 0.63 |
| Net Interest Income | - | 0.06 | 0.07 | -3.78 | -0.49 |
| Other Income Expense | - | 0.29 | -16.22 | -0.75 | -2.27 |
| Interest Income Non Operating | - | 0.06 | 0.09 | 0.36 | 0.14 |
| Interest Expense Non Operating | - | 0 | 0.02 | 4.14 | 0.63 |
| Net Non Operating Interest Income Expense | - | 0.06 | 0.07 | -3.78 | -0.49 |
| Pretax Income | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income From Continuing And Discontinued Operation | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income From Continuing Operation Net Minority Interest | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Net Income Common Stockholders | - | -9.37 | -29.32 | -22.65 | -30.06 |
| Net Income Including Noncontrolling Interests | - | -9.37 | -29.32 | -21.68 | -30.05 |
| Normalized Income | - | -9.66 | -13.10 | -20.93 | -27.78 |
| Diluted NI Availto Com Stockholders | - | -9.37 | -29.32 | -22.65 | -30.06 |
| Basic Average Shares | - | 12.18 | 11.89 | 18.66 | 47.93 |
| Diluted Average Shares | - | 12.18 | 11.89 | 18.66 | 47.93 |
| Reconciled Depreciation | - | 0.37 | 0.18 | 0.12 | 0.07 |
| Total Unusual Items | - | 0.29 | -16.22 | -0.75 | -2.27 |
| Total Unusual Items Excluding Goodwill | - | 0.29 | -16.22 | -0.75 | -2.27 |
| Preferred Stock Dividends | - | - | - | 0 | 0.01 |
| Special Income Charges | - | 0.29 | -16.22 | -0.44 | -3.86 |
| Other Special Charges | - | -0.29 | 16.22 | 0.44 | 3.68 |
| Write Off | -0.32 | 0 | - | - | - |
| Restructuring And Mergern Acquisition | - | - | - | 0 | 0.19 |
| Gain On Sale Of Security | - | - | - | -0.31 | 1.59 |
| General And Administrative Expense | - | 2.01 | 4.14 | 3.87 | 7.58 |
| Other Gand A | - | 2.01 | 4.14 | 3.87 | 7.58 |
| Other Operating Expenses | - | -0.21 | -0.04 | -0.06 | -0.71 |
| Otherunder Preferred Stock Dividend | - | - | 0 | 0.97 | 0 |
| Other Taxes | - | 0 | -0.33 | 0 | -0.11 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TuHURA Biosciences, Inc.this co. | HURA | $139M | -4.64 | 6.75 | -145.5% | -4.65 |
| Korro Bio, Inc. | KRRO | $161M | -1.38 | 3.13 | -228.0% | -2.20 |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Nano-X Imaging Ltd. | NNOX | $144M | -1.92 | 1.03 | -53.7% | -2.10 |
| Health Catalyst, Inc. | HCAT | $143M | -0.81 |
| - |
| - |
| - |
| - |
| 0.58 |
| -72.4% |
| -2.57 |
| AVITA Medical, Inc. | RCEL | $134M | -2.76 | -8.06 | 291.8% | -4.12 |
| SANUWAVE Health, Inc. | SNWV | $132M | 11.20 | 81.74 | 729.6% | 7.38 |
| MaxCyte, Inc. | MXCT | $132M | -2.95 | 0.77 | -26.0% | -3.23 |
| The Joint Corp. | JYNT | $117M | 40.32 | 7.80 | 19.3% | 118.19 |
| Peer Median | - | -1.38 | 2.08 | -39.9% | -2.20 | |